Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial
Year: 2024
Type: article
Study design: Clinical Trial
Source: Blood
Authors: Moritz Fürstenau, Adam Giza, Jonathan Weiss, Fanni Kleinert, Sandra Robrecht, Fabian Franzen, Janina Stumpf, Petra Langerbeins, Othman Al-Sawaf, Florian Simon, Anna-Maria Fink, Christof Schneider, Eugen Tausch, Johannes Schetelig, Peter Dreger, Sebastian Böttcher, Kirsten Fischer, Karl-Anton Kreuzer, Matthias Ritgen, Anke Schilhabel, Monika Brüggemann, Stephan Stilgenbauer, Barbara Eichhorst, Michael Hallek, Paula Cramer
Institutions: University of Cologne, University Hospital Cologne, Deutsche CLL Studiengruppe (DCLLSG), Universität Ulm, University Hospital Ulm, University Hospital Carl Gustav Carus, Technische Universität Dresden, Heidelberg University, University Hospital Heidelberg, Universitätsmedizin Rostock, University of Rostock, Christian-Albrechts-Universität zu Kiel, University Hospital Schleswig-Holstein
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4394822502